Related Experiment Video
Updated: Feb 15, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
The Congenital Heart Disease Genetic Network Study: Cohort description
Thanh T Hoang1, Elizabeth Goldmuntz2, Amy E Roberts3
1Department of Epidemiology, Human Genetics and Environmental Sciences, UTHealth School of Public Health, Houston, Texas, United States of America.
Insights
The Pediatric Cardiac Genomics Consortium (PCGC) established a large congenital heart defects (CHD) cohort. This study details the cohort
Area of Science:
- Genetics
- Pediatrics
- Cardiology
Background:
- Congenital heart defects (CHDs) represent a significant health concern in pediatric populations.
- Understanding the genetic underpinnings and associated factors of CHDs is crucial for improving patient outcomes.
- The Pediatric Cardiac Genomics Consortium (PCGC) initiated a study to gather comprehensive data on CHDs.
Purpose of the Study:
- To describe the characteristics of the PCGC cohort, a large cohort of patients with congenital heart defects.
- To analyze phenotype and genotype data across various CHD types and subtypes.
- To provide a reference for researchers interested in CHD genetics and outcomes.
Main Methods:
- Recruitment of 9,727 cases with CHDs and their parents across ten sites from 2010-2014.
- Collection of data through interviews and medical record abstraction, including case, parental, and neurodevelopmental outcomes.
- Statistical comparison of characteristics across different CHD types and subtypes.
Main Results:
- Eleven percent of cases received a genetic diagnosis; the majority without a genetic diagnosis had conotruncal heart defects or left ventricular outflow tract obstruction.
- Significant differences (p<0.05) were observed in case, parental, and neurodevelopmental characteristics across CHD types.
- Significant variations in characteristics were also noted across CHD subtypes.
Conclusions:
- The PCGC cohort is a valuable resource for studying genetic determinants of CHD risk and outcomes.
- A majority of CHDs in the cohort lack a specific genetic diagnosis, highlighting areas for future research.
- This cohort description serves as a foundational reference for collaborative research and utilization of PCGC data.
Abstract:
The Pediatric Cardiac Genomics Consortium (PCGC) designed the Congenital Heart Disease Genetic Network Study to provide phenotype and genotype data for a large congenital heart defects (CHDs) cohort. This article describes the PCGC cohort, overall and by major types of CHDs (e.g., conotruncal defects) and subtypes of conotrucal heart defects (e.g., tetralogy of Fallot) and left ventricular outflow tract obstructions (e.g., hypoplastic left heart syndrome). Cases with CHDs were recruited through ten sites, 2010-2014. Information on cases (N = 9,727) and their parents was collected through interviews and medical record abstraction. Four case characteristics, eleven parental characteristics, and thirteen parent-reported neurodevelopment outcomes were summarized using counts and frequencies and compared across CHD types and subtypes. Eleven percent of cases had a genetic diagnosis. Among cases without a genetic diagnosis, the majority had conotruncal heart defects (40%) or left ventricular outflow tract obstruction (21%). Across CHD types, there were significant differences (p<0.05) in the distribution of all four case characteristics (e.g., sex), four parental characteristics (e.g., maternal pregestational diabetes), and five neurodevelopmental outcomes (e.g., learning disabilities). Several characteristics (e.g., sex) were also significantly different across CHD subtypes. The PCGC cohort is one of the largest CHD cohorts available for the study of genetic determinants of risk and outcomes. The majority of cases do not have a genetic diagnosis. This description of the PCGC cohort, including differences across CHD types and subtypes, provides a reference work for investigators who are interested in collaborating with or using publically available resources from the PCGC.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Rheumatic Heart Disease I: Introduction
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Rheumatic Heart Disease III: Medical Management
What is Genetic Engineering?

